Digital Vision Screening Platform Aims to Decrease Vision Loss Rates for Patients With Eye Disorders
May 24, 2022 11:00 ET | Retina Technologies, Inc
NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) -- Retina Technologies, Inc. ("RetTech") is advancing the development of OcuVue™, an affordable, digital vision screening platform with integrated...
tarsus-logo-stacked-color-532x626.png
Tarsus to Present at Bank of America 2022 Healthcare Conference
May 06, 2022 09:00 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting
May 05, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
tarsus-logo-stacked-color-532x626.png
Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting
April 26, 2022 08:30 ET | Tarsus Pharmaceuticals, Inc
IRVINE, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize...
NovaSight Announces Successful Results of Pivotal Amblyopia Treatment Trial
March 10, 2022 08:15 ET | NovaSight
AIRPORT CITY, Israel, March 10, 2022 (GLOBE NEWSWIRE) -- NovaSight, a pediatric-focused eyecare company, announced positive pivotal data from its multicenter, randomized, controlled trial of...
tarsus-logo-stacked-color-532x626.png
Tarsus Expands Executive Leadership Team with the Appointment of José Trevejo, M.D., Ph.D., as Chief Medical Officer
February 03, 2022 09:00 ET | Tarsus Pharmaceuticals, Inc
Dr. Trevejo brings over 20 years of clinical development experience to Tarsus as it advances development of TP-03, the first potential treatment for Demodex blepharitis, and its pipeline programs ...
tarsus-logo-stacked-color-532x626.png
Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors
January 04, 2022 09:00 ET | Tarsus Pharmaceuticals, Inc
Dr. Yeu brings over 20 years of eye care experience, and is a highly regarded leader in clinical care and new product innovation IRVINE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tarsus...
Vision Benefits of America Donates $100,000 to the Pennsylvania Vision Foundation
December 16, 2021 09:00 ET | VISION BENEFITS OF AMERICA
PITTSBURGH, Dec. 16, 2021 (GLOBE NEWSWIRE) --  Vision Benefits of America, Inc. (VBA), a commercial group benefits organization, today announced a $100,000 donation to the Pennsylvania Vision...
Vision Benefits of America Joins Forces With Howell Benefit Services, Inc.
December 14, 2021 09:00 ET | VISION BENEFITS OF AMERICA
PITTSBURGH, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Vision Benefits of America, Inc. (VBA), a commercial group benefits organization, today announced its participation with WEBSURANCE, a fully-insured...
eyenuk_logo_redesign_2017_onecolor.png
Eyenuk Launches EyeArt AI System in South Africa in Collaboration with Discovery Health
December 07, 2021 10:36 ET | Eyenuk, Inc.
LOS ANGELES, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...